The Impact of Thromboprophylaxis on the Survival of Patients with Advanced Pancreatic Cancer. The Pancreatic Cancer and Tinzaparin (PaCT) Study
Authors:
- Michalis V. KaramouzisMichalis V. Karamouzis
- Ilias AthanasiadisIAIlias Athanasiadis
- Georgios SamelisGSGeorgios Samelis
- Christos VallilasCVChristos Vallilas
- Alexandros BokasABAlexandros Bokas
- Adamantia NikolaidiANAdamantia Nikolaidi
- Areti DimitriadouADAreti Dimitriadou
- Panagiotis SarantisPanagiotis Sarantis
- Nikolaos PistamaltzianNPNikolaos Pistamaltzian
- Dimitrios SchizasDimitrios Schizas
- Alexandros PapalamprosAPAlexandros Papalampros
- Evangelos FelekourasEFEvangelos Felekouras
Open Access
Abstract
Pancreatic cancer (PaC) induces a prothrombotic and hypercoagulable state. The aim of this study was to investigate the effect of tinzaparin in combination with chemotherapy. The PaCT (pancreatic cancer and tinzaparin) study was a retrospective observational study that collected data regarding progression free survival (PFS) in advanced or metastatic PaC patients who received thromboprophylaxis with tinzaparin during chemotherapy with nab-paclitaxel (N) and gemcitabine (G). The primary end point was to compare, from already published data, the PFS of patients receiving thromboprophylaxis with tinzaparin with the PFS of patients receiving chemotherapy with N–G but no thromboprophylaxis. Secondary end points were efficacy and safety of anticoagulation. In total, 110 PaC patients, 93% with advanced or metastatic disease, treated with N–G and tinzaparin (10,291 ± 1176 Anti-Xa IU, OD, median duration 8.7, IQR: 5.6–11.9 months) were enrolled. Of these, 52% were males and; the median age was 68 (40–86 years). The tumor was located to in the pancreatic head at in 45% of the patients. The median PFS was 7.9 months (IQR: 5.0–11.8 months). Out of 14 similar studies (involving 2994 patients) identified via systematic search, it was determined that the weighted PFS of patients receiving N–G but no anticoagulation was 5.6 months. Therefore, patients receiving tinzaparin had 39.54% higher PFS than patients without thromboprophylaxis (p < 0.05). During the follow-up period of 18.3 ± 11.7 months, three (2.7%) thrombotic events were recorded while two clinically relevant non-major bleeding events occurred (1.9%). In conclusion, PFS in advanced PaC patients undergoing chemotherapy is positively impacted by anticoagulation. Thromboprophylaxis with tinzaparin in treatment dose is efficient and safe.Keywords
This publication has 47 references indexed in Scilit:
- Epidemiology of cancer-associated venous thrombosisBlood, 2013
- The antineoplastic effect of low-molecular-weight heparins – a literature reviewContemporary Oncology, 2013
- Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection PercentagesPLOS Medicine, 2010
- Epidemiology and pathophysiology of cancer-associated thrombosisBritish Journal of Cancer, 2010
- Inflammation: A driving force speeds cancer metastasisCell Cycle, 2009
- Anti-cancer properties of low-molecular-weight heparin: Preclinical evidenceThrombosis and Haemostasis, 2009
- Pancreatic cancer: A model cancer for the study of the therapeutic effects of anticoagulantsWorld Journal of Gastrointestinal Oncology, 2009
- Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patientsAnnals of Oncology, 2007
- High risk of venous thrombosis in patients with pancreatic cancer: A cohort study of 202 patientsEuropean Journal of Cancer, 2006
- Cancer and venous thromboembolismThe Lancet Oncology, 2005